首页> 外文OA文献 >Optimizing pharmacotherapy in patients with rheumatoid arthritis : an individualized approach
【2h】

Optimizing pharmacotherapy in patients with rheumatoid arthritis : an individualized approach

机译:优化类风湿关节炎患者的药物治疗:个性化方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite the availability of different treatment options and strategies for RA patients, the response to treatment with DMARDs is still suboptimal. Strategies to optimize the pharmacological therapy of RA are therefore warranted. Two possible strategies to improve treatment outcome in RA were therefore studied in this thesis: improving adherence to DMARD-therapy and therapeutic drug monitoring of one of the biological agents: infliximab. First, improving adherence to traditional DMARDs could not only increase the effectiveness of a drug, but it could also indirectly delay the necessity of applying (more expensive) biological therapy as traditional DMARDs are more efficacious due to better adherence. In this thesis we show that, depending on the instrument used, 68% (CQR) and 60% (MARS) of the patients were adherent to DMARDs. None of the possible risk factors for non-adherence were however strongly related to adherence, implying that no general risk factor seems to be powerful enough as a possible screening tool or target for adherence-improving interventions. Research is needed on the efficacy of interventions that are tailored to individual primary reason(s) for non-adherence. Therapeutic drug monitoring (TDM) of serumlevels of anti-TNF-alpha biopharmaceuticals could be a strategy to improve efficacy of these drugs. Data derived from both rheumatology and gastro-enterology patients suggest that serum trough concentrations of (anti) infliximab, (anti)adalimumab and etanercept may be used to optimize dose regimens and prevent prolonged use of ineffective therapy. In this thesis we demonstrate that TDM of inflixmab serum trough levels could be useful in two scenarios: the prediction of 6 months response at 6 weeks, and the detection of the significant number of patients with adequate disease activity despite having nontherapeutical infliximab levels. TDM was not effective in predicting which patients benefit from dose escalation
机译:尽管对于RA患者有不同的治疗选择和策略,但对DMARDs的治疗反应仍不理想。因此,有必要优化RA的药物治疗策略。因此,本论文研究了两种改善RA疗效的可能策略:提高对DMARD治疗的依从性和对一种生物制剂英夫利昔单抗的治疗药物监测。首先,改善对传统DMARD的依从性不仅可以提高药物的有效性,而且还可以间接延迟应用(更昂贵的)生物疗法的必要性,因为传统DMARD由于具有更好的依从性而更加有效。在本文中,我们表明,根据所使用的仪器,68%(CQR)和60%(MARS)的患者坚持使用DMARD。但是,没有任何可能的非依从性危险因素与依从性没有强烈关系,这意味着没有一般性的危险因素似乎足以作为改善依从性干预措施的筛选工具或目标。需要针对针对不遵守的个人主要原因量身定制的干预措施的有效性进行研究。血清抗TNF-α生物药物的治疗药物监测(TDM)可能是提高这些药物疗效的一种策略。来自风湿病学和胃肠病学患者的数据表明,(抗)英夫利昔单抗,(抗)阿达木单抗和依那西普的血清谷浓度可用于优化剂量方案并防止长期使用无效疗法。在本论文中,我们证明了英夫利昔单抗血清谷水平的TDM在两种情况下可能是有用的:预测6周时6个月的反应,以及检测到尽管具有非治疗性英夫利昔单抗水平但仍具有足够疾病活动性的大量患者。 TDM无法有效地预测哪些患者将从剂量增加中受益

著录项

  • 作者

    Bemt B.J.F. van den;

  • 作者单位
  • 年度 2009
  • 总页数
  • 原文格式 PDF
  • 正文语种
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号